(Q73526348)

English

Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease

scientific article published on 01 July 1997

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9230143%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9230143%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

coronary artery disease

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9230143%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

author name string

B G Brown

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9230143%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

J Bardsley

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9230143%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

D Poulin

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9230143%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

L A Hillger

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9230143%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

A Dowdy

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9230143%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

X Q Zhao

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9230143%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

J J Albers

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9230143%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

R H Knopp

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9230143%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

language of work or name

0 references

publication date

1 July 1997

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9230143%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

American Journal of Cardiology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9230143%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

80

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9230143%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

111-115

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9230143%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9230143%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900303-2

7 January 2021

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900303-2

7 January 2021

Nicotinic Acid Maculopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900303-2

7 January 2021

Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900303-2

7 January 2021

Jaundice occurring during nicotinic acid therapy for hypercholesteremia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900303-2

7 January 2021

Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900303-2

7 January 2021

Fulminant hepatic failure after ingestion of sustained-release nicotinic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900303-2

7 January 2021

Hepatic toxicity of unmodified and time-release preparations of niacin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900303-2

7 January 2021

Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900303-2

7 January 2021

A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900303-2

7 January 2021

Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900303-2

7 January 2021

Treatment of hypercholesterolemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900303-2

7 January 2021

Nicotinic acid-associated myopathy: a report of three cases

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900303-2

7 January 2021

Niacin-induced myopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900303-2

7 January 2021

Lovastatin, nicotinic acid, and rhabdomyolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900303-2

7 January 2021

Nicotinic acid-induced fulminant hepatic failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900303-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0002-9149(97)00303-2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9230143%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9230143%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q73526348&oldid=1753511100"